Intellia Therapeutics, Inc. (NTLA) vs Xencor, Inc. (XNCR)

Intellia Therapeutics, Inc. and Xencor, Inc. are both Biotechnology companies. Intellia Therapeutics, Inc. and Xencor, Inc. are of similar size ($1.8B and $1.7B). Intellia Therapeutics, Inc. grew revenue faster over the last twelve months: 12.6% against −28.6%. Xencor, Inc. has the higher net margin (−155.6% vs −672.2%) and the lower return on invested capital (−288.7% vs −91.3%). Across the 16 metrics below, Xencor, Inc. leads on 10 and Intellia Therapeutics, Inc. on 6.

Valuation

Metric NTLA XNCR Biotechnology median
P/E n/m n/m 7.88
P/S 26.36 17.20 11.47
P/B 2.16 3.59 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 19.00 13.99 10.73
Earnings yield (28.60%) (9.12%) (28.84%)
Free cash flow yield (22.23%) (11.59%) (23.03%)

Profitability

Metric NTLA XNCR Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (711.66%) (205.84%) 0.00%
Net margin (672.16%) (155.59%) 0.00%
Free cash flow margin (585.82%) (198.42%) 0.00%
Return on equity (55.44%) (29.07%) (57.72%)
Return on assets (45.55%) (20.36%) (49.22%)
Return on invested capital (91.28%) (288.71%) 0.00%

Growth

Metric NTLA XNCR Biotechnology median
Revenue growth (TTM) 12.58% (28.56%) 5.64%
EPS growth (last fiscal year) 27.43% 65.36% —
Revenue growth, 5-year CAGR 3.13% 0.47% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NTLA XNCR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.65 6.39 4.73
Net debt to EBITDA 1.06 2.51 0.96

Dividend

Metric NTLA XNCR Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric NTLA XNCR Biotechnology median
Market cap 1.72b 1.79b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack